Recombinant human interferon-β for condylomata acuminata: A randomized, double-blind, placebo-controlled study of intralesional therapy

International Journal of STD and AIDS

Volumn 8, Issue 10, 1997, Pages 614-621

  Bornstein, Jacob ^a,b   Pascal, Bruno ^a   Zarfati, Doron ^a   Goldshmid, Nimrod ^a   Abramovici, Haim ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

Condylomata acuminata; Human papillomavirus; Recombinant interferon; Therapy

Indexed keywords

PLACEBO; RECOMBINANT BETA INTERFERON;

ARTICLE; BIOPSY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; INTRADERMAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; WART VIRUS;

ADOLESCENT; ADULT; BIOPSY; CONDYLOMATA ACUMINATA; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON-BETA; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; TREATMENT OUTCOME;

EID: 0030879839     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462971918878     Document Type: Article

References (40)

1. Oriel JD. Condylomata acuminata as a sexually transmitted disease. Dermatol Clinics 1983;1:93-102
2. Condylomata acuminata - United States. MMWR 1983; 32:306-8
3. Sciffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64
4. Beudenon S, Kremsdorf D, Croissant O, Jablonska S, Wain-Hobson S, Orth G. A novel type of papillomavirus associated with genital neoplasias. Nature 1986;321:246-9
5. Handley J, Dinsmore W. Treatment of anogenital warts. J Eur Acad Dermatol Venereal 1994;3:251-65
6. Ferenczy A. Epidemiology and clinical pathophysiology of condylomata acuminata. Am J Obstet Gynecol 1995;172: 1331-9
7. Reichman RC. Human papillomavirus infections. In: Wilson JD, Braunwald E, Isselbacher KJ, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 1991:741-3
8. Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. N Engl J Med 1985;313:784-8
9. Borden EC, Hogan TF, Voelkel JG. Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res 1982;42:4953-89
10. Dianzani F. Viral interference and interferon. New Trends Therapy Leukemia Lymphoma 1987;2:3
11. Revel M, Schattner A, Wallach D. Monitoring of interferon therapy, diagnosis of viral diseases, and detection of interferon deficiencies by assay of interferon-induced enzyme in human peripheral white blood cells. In: Kono R, Vilcek J, eds. The Clinical Potential of Interferons. Tokyo: University of Tokyo Press, 1982:353-67
12. Turek L, Byrne JC, Lowing DR. Interferon induces morphologic reversion with elimination of extra-chromosomal viral genomes in bovine papillomavirus-transformed mouse cells. Proc Natl Acad Sci USA 1982;79:7914-18
13. Eron LJ, Judsorv F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986;315:1059-64
14. Friedman-Kien A, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988;259:533-8
15. Gross G, Ikenberg H, Roussaki A, et al. Systemic treatment of condylomata acuminata with recombinant interferon-alpha-2a: low-dose superior to high-dose regimen. Chemotherapy 1986;32:537-51
16. Reichman RC, Oakes D, Bonnez W, et al. Treatment of condylomata acuminata with three different interferons administered intralesionally. Ann Int Med 1988;108:675-9
17. Schonfeld A, Schattner A, Crespi M, et al. Intramuscular human interferon beta treatment of condylomata acuminata. Lancet 1984;1:1038-12
18. Vance JC, Bart BJ, Hansen RC, et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986;122:272-7
19. Gentile G, Formelli G, Busacchi P, Pelusi G. Systemic interferon therapy for female florid genital condylomata. Clin Exp Obstet Gynecol 1994;21:198-202
20. Condylomata International Collaborative Study Group. Recurrent condylomata acuminata treated with recombinant interferon alpha 2a. A multicenter double-blind placebo-controlled clinical trial. Acta Derm Venereol Stock 1993;73:223-6
21. Reichel RP, Fitz R, Newmann R, et al. Clinical study with recombinant interferon gamma versus inteferon alpha-2c in patients with condylomata acuminata. Int J STD AIDS 1992;3:350-4
22. Yliskoski M, Syrjanen K, Syrjanen S, Saarikoski S, Nethersell A. Systemic alpha-interferon (wellferon) treatment of genital human papillomavirus (HPV) type 8, 11, 16 and 18 infections: double blind, placebo controlled trial. Gynecol Oncol 1991;43:55-60
23. Condylomata International Collaborative Study Group. A comparison of interferon alpha 2a and podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1991;67:394-9
24. Condylomata International Collaborative Study Group. Recurrent condylomata acuminata treated with recombinant inteferon alpha 2a. A multicenter double blind placebo controlled clinical trial. JAMA 1991;265:2684-7
25. Welander CE, Homesley HD, Smiles KA, Peets EA. Intralesional Interferon alfa-2b for the treatment of genital warts. Am J Obstet Gynecol 1990;162:348-54
26. Sica G, Lama G, Tartaglione R. Effects of natural beta-interferon and recombinant alpha-2b-interferon on proliferation, glucocorticoid receptor content, and antigen expression in cultured HL-60 cells. Cancer 1990;65:920-5
27. Borden EC, Groveman DS, Nasu T. Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1990;132:800-3
28. Johns TG, Mackay IR, Callister KA. Antiproliferative potencies of Interferon on melanoma cell lines and xenografts: higher efficacy of Interferon β. J Natl Cancer Inst 1992;84:1185-9
29. de Grado WF, Wasserman ZR, Chowdry V. Sequence and structural homologies among type I and type II interferons. Nature 1987;300:379-81
30. De Marco F, Giannoni F, Marcante ML. Interferon-β strong cytopathic effect on human papillomavirus type 16-immortalized HPK-IA cell line, unexpectedly not shared by interferon-α. J Gen Virol 1995;76:445-50
31. Taniguchi T, Mantei N, Schwarzstein M. Human leukocyte and fibroblast interferons are structurally related. Nature 1980;285:547-9
32. Ruzicka FJ, Jach ME, Borden EC. Binding of recombinant-produced interferon βser to human lymphoblastoid cells. Biol Chem 1987;262:16142-9
33. Platanias LC, Uddin S, Colamonici OR. Tyrosine phosphorylation of the α and β subunits of the type I interferon receptor. Biol Chem 1994;269:17761-4
34. Hawkins M, Hornin GS, Konrad M. Phase I evaluation of a synthetic mutant of beta-interferon. Cancer Res 1985;45:5914-20
35. Hu E, Horning SJ. Phase I study of recombinant interferon beta in patients with advanced cancer. J Biol Response Mod 1987;6:121-9
36. Olmos L, Vilata J, Rodriguez-Pichardo A, Lloret A, Ojeda A, Calderon MD. Double blind, randomized clinical trial on the effect of interferon beta on the treatment of condylomata acuminata. Int J STD AIDS 1994;5:182-5
37. Barrasso R, de Brux J, Croissant O, Orth G. High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia. N Engl J Med 1987;317:916-22
38. Riou G, Favre M, Jeannel D, Bourhis J, le Doussal V, Orth G. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 1990;335:1171-4
39. Saiki RK, Scarf SJ, Fallona F, et al. Enzymatic amplification of β globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985;230:1350-3
40. Scott GM, Csonka FW. Effects of injections of small doses of human fibroblast interferon into genital warts. Br J Vener Dis 1979;55:442-8